title: [Combined treatment: regimens, indications and safety profile].
abstract: Statins are the current basis of lipid-lowering therapy, despite which may have limitations on efficacy and safety. In high risk patients who do not achieve current lipid goals, in those intolerant to statins or those with atherogenic dyslipidemia, it is possible combine two or more lipid lowering drugs, including statins, ezetimibe, bile acid sequestrants, fibrates, niacin and prescription omega-3 fatty acids. However, for most of these combination therapies pivotal data on clinical outcomes are still lacking.
authors.affiliation: UCERV, Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, España.
authors.forename: Ovidio
authors.initials: O
authors.lastname: Muñiz Grijalvo
authors.forename: Jose
authors.initials: J
authors.lastname: Villar Ortiz
mesh_terms: D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents
keywords: Combined lipid lowering therapie; Estatinas; Hipercolesterolemia; Hypercholesterolemia; Statins; Tratamiento hipolipemiante combinado